Clin2
NCT06959784Likely a fitEnrolling by invitation

A study on new diabetes drugs for heart health and remission

Diabetes MellitusCardiovascular DiseasesCerebrovascular Disease

Treatments studied

Part of Brain & nervous system, Heart & circulation, Hormones & metabolism clinical trials.

This trial tests if newer diabetes medications can reduce heart risk and help achieve diabetes remission in people newly diagnosed with type 2 diabetes. It may be an option if you have not taken diabetes drugs before or stopped them over three months ago, and your blood sugar and weight are in certain ranges.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
142 people
Ages
30 years to 70 years
Study type
Interventional

Who can take part

  • You have been diagnosed with type 2 diabetes within the last year
  • You have not taken any diabetes medication before, or stopped taking it more than three months ago
  • Your blood sugar level is high: fasting blood sugar over 7, or after meals over 11.1
  • You are between 30 and 70 years old
  • Your A1c (average blood sugar level over 3 months) is between 7% and 10%

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07483801Not yet recruiting· Phase 4
Study of two diabetes drugs for weight and blood pressure

This trial tests two medications (semaglutide and tirzepatide) to see how they affect blood pressure and heart function in people with different body weights and blood pressures. You would receive one of the drugs and have your heart and blood pressure monitored.

Cambridge, Cambridgeshire
NCT06082063Recruiting· Phase 3
Reducing heart disease risk in type 1 diabetes

This trial tests a combination of treatments to lower the risk of heart disease and kidney problems in people with type 1 diabetes who already have some complications or higher risk. If you qualify, you will receive extra care aimed at preventing heart attacks, strokes, and kidney failure.

Copenhagen
NCT07244003Recruiting· Phase 4
Testing metformin with two newer diabetes drugs

This trial is testing if adding a combination of SGLT-2 inhibitor and GLP-1 receptor agonist to metformin can improve blood sugar control in people with type 2 diabetes who are not meeting their goals on metformin alone or with one other pill.

Tianjin, Tianjin Municipality
NCT07109700Recruiting· Phase 2
New injectable study for type 2 diabetes

This study tests a new once-weekly injectable medication (HDM1005) for people with type 2 diabetes whose blood sugar is not well controlled by diet and exercise or metformin alone. It aims to help lower blood sugar and may also support weight loss.

Beijing, Beijing Municipality
NCT06613854Recruiting· Phase 4
Early combination therapy for type 2 diabetes

This study tests if starting two newer diabetes drugs (empagliflozin and semaglutide) soon after diagnosis, along with metformin, helps control blood sugar better than metformin alone. It's for people diagnosed with type 2 diabetes in the last two years who are already taking a high dose of metformin.

Ljubljana
NCT07254572Recruiting· Phase 4
Comparing diabetes drugs for heart health in prediabetes

This trial tests whether certain diabetes medications can help prevent worsening of heart disease in people who have prediabetes (higher than normal blood sugar, but not yet diabetes). It may be a good fit if you have known coronary artery disease and prediabetes.

Warsaw

Hear when a new Diabetes Mellitus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.